Navigation Links
An Epitope Tagging Vector for Gene Expression in Mammalian Cells

An Epitope Tagging Vector for Gene Expression in Mammalian Cells Use tag-specific antibodies to study expressed genes

Tanya Hosfield Quinn Lu
Stratagene


The pCMV-Tag1 vector is an epitope tagging vector designed for gene expression in mammalian cells. A target gene inserted into the pCMV-Tag1 vector can be tagged with the FLAG epitope (N-terminal, C-terminal or internal tagging), the c-myc epitope (C-terminal) or both the FLAG (N-terminal) and c-myc (C-terminal) epitopes. Tagged constructs generated in the pCMV-Tag1 vector can be transfected into mammalian cells, and the tagged gene product can be easily characterized using commercially available, tag-specific antibodies.

The epitope tagging technique involves fusion of a protein of interest to a peptide-epitope that is recognized by a readily available antibody. In this technique, expression of the fusion protein is monitored using a tag-specific antibody, allowing a new protein to be studied without generating a new, specific antibody to that protein. Epitope tagging can be used to localize gene products in living cells, identify associated proteins, track movement of fusion proteins within the cell, or characterize new proteins by immunoprecipitation.1-3

pCMV-Tag1 Vector for Epitope Tagging

Stratagenes pCMV-Tag1 vector is a general mammalian expression vector that contains the FLAG and c-myc epitopes positioned for either terminal or internal tagging of a target protein. The pCMV-Tag1 vector (figure 1) is derived from the pCMV-Script vector4 and contains sequences for the FLAG and c-myc epitopes. These specific epitope tags are small, not interfering with the function of the target protein, and highly immunoreactive. The FLAG epitope is a synthetic epitope that consists of eight amino acid residues (DYKDDDDK).5 The c-myc epitope is derived from the human c-myc gene and contains 10 amino acid residues (EQKLISEEDL).6 In addition to the epitope tag sequences, the pCMV-Tag1 vector contains features for expression of fusion proteins in eukaryotic cells. The cytomegalovirus (CMV) promoter allows constitutive expression of the cloned DNA in a wide variety of mammalian cell lines. The neomycin-resistance gene is under control of both the prokaryotic b-lactamase promoter to provide kanamycin resistance in bacteria and the SV40 early promoter to provide G418 resistance in mammalian cells. The multiple cloning site (MCS) of the pCMV-Tag1 vector is arranged to allow a variety of cloning strategies to be used, resulting in C-terminal, N-terminal or internal tagging of the protein of interest. A Kozak consensus sequence of GCC(A or G)CCATGG7 provides optimal expression of the fusion protein when the N-terminal FLAG epitope tag is used. Other cloning options, which require fusion proteins to include their own translational start sequence, are also possible.

Cloning Strategies for Epitope Tagging

Epitope Tag

Tag Location

Cloning Site

Kozak Sequence

A

FLAG

C-terminus

MCS 1

Insert supplied

B

FLAG

N-terminus

Bgl II

Vector supplied

C

FLAG and
c-myc

N and
C-termini

Bgl II and MCS 2

Vector supplied

D

c-myc

C-terminus

MCS 1 and 2

Insert supplied

E

FLAG

Internal

MCS 1 and Bgl II

Insert supplied

F

No tag

N/A

MCS 1 or MCS 1 and 2

Insert supplied

A gene of interest can be efficiently cloned into the pCMV-Tag1 vector for terminal tagging with either the FLAG or c-myc epitopes or internal tagging with the FLAG epitope. With these choices, researchers can optimize the tagging position for each protein they study. The cloning strategies for various tagging choices are summarized in figure 2.

Expression in the pCMV-Tag1 Vector

The firefly luciferase gene was cloned into the Bgl II and Xho I sites of the pCMV-Tag1 vector such that the luciferase protein was tagged with the FLAG epitope at the N-terminus and the c-myc epitope at the C-terminus. We chose the luciferase gene because it can be assayed both enzymatically and immunologically. This construct was transiently transfected into Chinese hamster ovary (CHO) cells, and the cell lysates were assayed for luciferase activity. The results of these luciferase assays (figure 3) demonstrate that luciferase tagged with both FLAG and c-myc is biologically active. Control transfections, with the reagents alone or the pCMV-Tag1 vector without the luciferase insert, show low background levels.

Figure 3

To demonstrate the easy detection of the epitope tags, we performed Western blot analyses of cell lysates derived from cells transfected with the pCMV-Tag1 vector and the pCMV-Tag1 vector with the luciferase insert (figure 4). Aliquots of these samples were simultaneously loaded and electrophoresed in three separate gels.

Figure 4

The three gels were then probed individually with either anti-luciferase, anti-FLAG or anti-c-myc antibodies. The results indicate that the fusion protein, composed of FLAG-luciferase-c-myc, is easily detected by Western blot analysis.

In order to demonstrate G418 resistance in the pCMV-Tag1 vector, we used Stratagenes Mammalian Transfection Kit to obtain stable CHO cell lines containing either the pCMV-Tag1 vector or the pCMV-Tag1 vector with the luciferase insert. For the cells transfected with the pCMV-Tag1 vector containing the luciferase gene, the luciferase assay was used to verify the presence of the fusion protein (data not shown).

Conclusions

The pCMV-Tag1 expression vector incorporates the small and highly immunoreactive FLAG and c-myc epitopes into constructs for N-terminal, C-terminal and internal tagging. These tags eliminate the need for raising specific antisera to study a target gene. The epitope tags can be easily detected in transfected cells using well-characterized, commercially available antibodies. The pCMV-Tag1 vector offers a fast, versatile and reliable method for analyzing the function of gene products in vivo.

Acknowledgments

We would like to thank Denise Wyborski, Cathy Chang, Xu Li, Chao-Feng Zheng, Wei-Ping Yang, Phyllis Frosst and the members of the Gerace lab at TSRI for suggestions, discussion and materials.

REFERENCES
  1. Kolodziej, P.A., and Young, R.A. (1991) Methods Enzymol. 194: 508-519.

  2. Cravchik, A., and Matus, A. (1993) Gene 137: 139-143.

  3. Sells, M., and Chernoff, J. (1995) Gene 152: 187-189.

  4. Hosfield, T., Padgett, K., Sanchez, T., and Lu, Q. (1997) Strategies 10: 68-69.

  5. Hopp, H.P., et al. (1988) Biotechnology 6: 1204-1210.

  6. Evan, G.I., et al. (1985) Mol. Cell Biol. 5: 3610-3616.

  7. Kozak, M. (1991) J. Biol. Chem. 266: 19867-19870.


'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Epitope-Tagging Vectors for Functional Analysis in Yeast
2. High-Level Protein Expression, One-Column Purification, and FLAG Epitope Tagging in E. coli
3. A New C-Terminal GST Vector for Protein Production in S. pombe
4. Generate Adenovirus Vectors in E. coli by Homologous Recombination with the AdEasy Adenoviral Vector System
5. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
6. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
7. Efficiently Insert Unique Restriction Sites into Plasmid Vectors
8. High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors
9. A New Lambda Vector for Mammalian Expression
10. Versatile Reporter Vectors for Monitoring Viral Transduction
11. High-Titer Retroviral Vectors for Gene Delivery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Epitope Tagging Vector for Gene Expression Mammalian Cells

(Date:11/24/2009)..., TSXVENTURE:HTL , TORONTO,Nov.24/PRNewswir...yCalottoCapitalInc.,aleadingproviderofadvancedlase...tilityclinicmarkets,todayreportedoperationalandfin...09. , ,Q32009Highlights,-Revenuewas$1.46millionc...was66.3percentcomparedwith66.1percentinQ3,2008,-Ne...
(Date:11/24/2009)..., SANDIEGO,Nov.24,2009/PRNewswire-FirstCall/--Ar...odaythatthecompanyisscheduledtopresentatthePiperJa...9at11:30a.m.EasternTime(8:30a.m.PacificTime)attheN...esident andChiefExecutiveOfficer,isscheduledtoprov...lopmentanddiscoveryprograms. ,, Aliveaudiowebca...
(Date:11/24/2009)..., BOZEN,Italy,November24/PRNewswire/--HealthRobo...tventurewithagroupofselected,investors.Thisrecentl...eHealthRoboticsCanada,Inc.andwillmarket,install,an...,whichincludesthe,revolutionaryproductofferingsi.v...csCanadaInc.willalsoprovideassistanceonan"asneeded...
(Date:11/24/2009)... Chemical Abstracts Service (...eports that China,s patent office is now the world...ns in chemistry. China trailed Japan,s patent offi...WIPO), and the United States Patent and Trademark ...the USPTO in 2005, WIPO in 2006, and exceeded Japa...
Breaking Biology Technology:Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
... Accelerate Trials and Commercialization, PALO AL...etin Board: AVGO), a late-stage biotechnology comp...ics for neurodegenerative,diseases, announced toda...private offering of Preferred Stock and warrants. ... and in exchange sold,3,110 shares of newly design...
... Sep. 26 NFL Hall of Fame,legendary wide receiver...am,of celebrated athletes and entertainers as a pa...ife, Inc. (Amex: SGN ) and Athletes for Life,("AF...d products and,technologies. He has joined such su...n, Rocket Ismail, Jerry Rice, Dwight Clark, and Le...
...s to illustrate wide applicability of JuvImmune an...rms, PLEASANTON, Calif., Sept. 26 Juvaris BioThe...entations at the upcoming IDSA,meeting on October ...ltiple,species of JuvImmune immunostimulant and Ju... hepatitis and HSV-2. "We are pleased that the co...
Other Biology Technology:Avicena Group Announces Closing of Private Offering 2NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team 2Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007 2
(Date:11/24/2009)...f debate. A high-profile study a few years ago sug...rbon from trees and leaves, evidence for a very cl...stems. , But new research from the University of...lgae provide a much richer diet for fish and other...s week in the Proceedings of the National Academy...
(Date:11/23/2009)...d strain of the deadly superbug MRSAan infection-c...csposes a far greater health threat than previousl...rding to a study in the December issue of Emergin...ily picked up in fitness centers, schools, and oth...den of MRSA within hospitals, the report found. ,...
(Date:11/23/2009)...nts gathered this week for the seventh annual Nati... This year,s topic, "Synthetic Biology," brought t...hers to explore the engineering, scientific, and s...thetic biology. , Bonnie L. Bassler, professor o...is year,s conference chair, challenged the attende...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Why Huntingtons Shows Up in Midlife 48864 1Why Huntingtons Shows Up in Midlife 48864 2New 3M CDI System Promotes Lasting Clinical Documentation Improvement 48861 1New 3M CDI System Promotes Lasting Clinical Documentation Improvement 48861 2New 3M CDI System Promotes Lasting Clinical Documentation Improvement 48861 3Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 48858 1Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 48858 2Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 48858 3
...ritical portions of the brain in those who are obe...ers have reported in the March issue of the journa...findings in obese mice show that a sensor in the b...causing a cascade of events that keeps energy bala...of the metabolic pathway remains ready to respond....
... study at UCL (University College London) finds th...ve in many species of insect including the butterf... fatigue. , The team found that when the male inse...-- the female butterfly becomes more sexually ramp... and put less effort into mating. , In some po...
...tronger than steel and more elastic than rubber: s...sistance to tearing, and toughness. Spider silk wo...dical and technical applications, and researchers ...ts and imitating their technique. A team lead by T...ch has now made a step in the right direction. As ...
Other Biology News:In obesity, brain becomes 'unaware' of fat 2In obesity, brain becomes 'unaware' of fat 3Male-killing bacteria makes female butterflies more promiscuous 2Fascinating spider silk 2
...genomic DNA from plants in 96 well plates. Plant m... well plate using large zirconia beads optimized f... velocity plate shaker (available through Mo Bio)....rane spin filter plate. The DNA is washed and then...
...ler with 384-well reaction module is used for nucl...quipped with an interchangeable, 384-well reaction...orithm temperature monitoring and control and ramp.... It includes the iCycler base with 384-well react...
... systems, known as ChemiArrayTM Mouse Cytokine Ant...h current methodologies. Besides the ability to de... a more accurate reflection of active cytokine lev...nd no amplification step is needed. Furthermore, i...
RAT LD NORMAL TISSUE ARRAY from BioGenex
Biology Products: